OCUGEN INC. - COMMON STOCK

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

01 Apr 2022 07:37:00 By Nasdaq GlobeNewswire

Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors

23 Mar 2022 07:44:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance

21 Mar 2022 18:36:00 By Nasdaq GlobeNewswire

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

18 Mar 2022 17:56:00 By Nasdaq GlobeNewswire

Ocugen, Inc. to Present at the 34th Annual ROTH Conference

09 Mar 2022 07:11:00 By Nasdaq GlobeNewswire

Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization (EUA) Request

04 Mar 2022 07:01:00 By Nasdaq GlobeNewswire

Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results

25 Feb 2022 07:31:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Pricing of $53.5 Million Public Offering of Common Stock

22 Feb 2022 21:43:33 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

22 Feb 2022 16:02:55 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Friday, February 25 at 8:30 a.m. ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update

18 Feb 2022 18:12:00 By Nasdaq GlobeNewswire